Skip to main content
. 2019 Nov 22;39(11):BSR20192298. doi: 10.1042/BSR20192298

Figure 4. FOXA2 directly targets miR-942.

Figure 4

(A) TargetScan7.2 was used to predict the possible target genes for miR-942. (B) Dual-luciferase reporter assay was used to analyze the fluorescence activity of FOXA2 in overexpressed miR-942 (n=3, **P<0.001, vs. Blank). (C) Dual-luciferase reporter assay was used to analyze the fluorescence activity of FOXA2 in low-expressed miR-942 (n=3, **P<0.001, vs. Blank) (D) QRT-PCR was used to detect FOXA2 expression in 31 BCa patients and 31 adjacent tissues (n=3, **P<0.001, vs. normal). (E) miR-942 was in negative correlation with FOXA2 in 31 BCa patient samples (r = −0.429, P=0.016). (F,G) Western blotting was used to detect the FOXA2 expression in BCa patients and adjacent tissues (n=3, **P<0.001, vs. normal 1; ##P<0.001, vs. normal 2). (H,I) Western blotting was used to detect the FOXA2 expression in BCa patients and adjacent tissues (n=3, **P<0.001, vs. normal 4; ##P<0.001, vs. normal 5; ∧∧P<0.001, vs. normal 6). (J) Kaplan–Meier method was used to analyze the relationship between FOXA2 and survival without distant metastasis in BCa patients.